A couple quick items from around the world.
First off, PharmaTimes reports that Gilead's HCV drug Sovaldi (sofosbuvir) has received European approval -- which follows FDA approval in December. It is part of a combination therapy with peg-interferon and ribavarin. However, this first ever oral hepatitis C drug is also approved as a treatment option for those patients who don't tolerate interferon. The first drug of its kind to make that claim. The drug is expected to increase the cure rate among HCV patients.
Next up, Takeda received word of approval of Adcetris in Japan. The ADC drug, developed and commercialized in partnership with Seattle Genetics, will be used to treat refractory Hodgkins' patients. Adcetris was approved similarly in the US in August 2011 and in October 2012 in the EU. Takeda is responsible for marketing the drug in Japan, and Seattle Genetics will earn $9 M in milestone payments. See PharmaTimes.
Posted by Bruce Lehr Jan 20th 2014.